Dry Powder Inhalation
SPARC's DPI is a pre-metered, 60 doses, breath activated and medium resistant, high efficiency device. It consistently delivers higher amount of drug to lungs by reducing oropharyngeal deposition. Irrespective of the age of the patient, it is easy to use by pediatric, geriatric and adult patients. This small and easy to carry device is compliant to the stringent USFDA and European regulatory requirements.
The salient features of the device are
- Uniform dose delivery independent of patient effort
- Gives a visual, audible and tactile feedback that the dose has been administered
- Eliminates double dosing
- No dose wastage if dose is not inhaled by patient
- Fail-safe dose counter
- Glow-in-the-dark feature for easy night-time use
- Feature for assisting visually impaired, as reminder to refill device, when 8 doses remain
In head on trials versus the innovator device, SPARC’s DPI demonstrated statistically and clinically significant improvement from the base line on all efficacy parameters studied. There was also a reduction in use of rescue medication, by day and night time asthma symptoms.
In study examining the handling, usability and user satisfaction of SPARC's DPI device in children and adults with Asthma and Chronic Obstructive Pulmonary Disease, the data shows that the subjects were able to use the SPARC DPI successfully and found the device to be user-friendly.
Asthma affects over 334 million patients worldwide. Asthma and COPD is the third highest cause of death in United States currently and is expected to be the 3rd highest cause of death globally by 2020. Total asthma market in developed countries (US, Europe and Japan) is expected to reach $27 Bn by 2017. Inhalation drugs contribute 70% of this market.